Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Plasma cell 1Genitourinary 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 116Bortezomib 63Cyclophosphamide 51Lenalidomide 49Calcium Dobesilate 46Melphalan 37pomalidomide 36fludarabine 28Filgrastim 26fludarabine phosphate 23carfilzomib 22daratumumab 21Whole-Body Irradiation 17Granulocyte Colony-Stimulating Factor 17Mycophenolic Acid 15Antilymphocyte Serum 15dexamethasone acetate 14Tacrolimus 14Thalidomide 13Cyclosporine 13Busulfan 13Radiotherapy 12Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Stem Cell Transplantation 9Rituximab 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × paricalcitol × Plasma cell × Clear all
NCT00258258 2013-02-01

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Roswell Park Cancer Institute

Phase 1 Terminated
7 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡